文献速递皮肤肿瘤

真实世界中一线转移性黑色素瘤伊匹木单抗联合纳武利尤单抗与纳武利尤单抗单药的疗效与安全性比较

The efficacy and safety of first-line metastatic melanoma treatment with ipilimumab + nivolumab vs. nivolumab in a real-world setting.
PubMed 文献 · Br J Dermatol · 2025-01-01

本研究基于法国MelBase前瞻性队列2013-2022年数据,比较纳武利尤单抗单药(N,n=406)与伊匹木单抗联合纳武利尤单抗(I+N,n=416)一线治疗IIIc或IV期黑色素瘤的疗效与安全性。主要终点36个月总生存率在I+N组为57.1%(95%CI 50.7-64.2),高于N组的46.6%(95%CI 41.6-52.1),HR=1.4(95%CI 1.1-1.8);36个月无进展生存率I+N组42.3%显著优于N组21.9%(HR=1.6,95%CI 1.4-1.9);两组客观缓解率均为44%,总体不良反应发生率相当(82% vs 84%),≥3级严重毒性I+N组更常见但未达统计学显著(41% vs 29%)。

要点

  • 真实世界中I+N较N单药显著改善36个月PFS(42.3% vs 21.9%,HR=1.6)
  • I+N组36个月OS高于N组(57.1% vs 46.6%,HR=1.4)
  • 两组ORR均为44%,总体不良反应发生率相当,≥3级毒性I+N组数值更高但未显著

核心结论

  • 真实世界结果与Checkmate 067一致,支持I+N作为转移性黑色素瘤一线治疗。
  • I+N较N单药显著改善36个月PFS,36个月OS亦有提高。
  • 本研究中ORR及毒性发生率低于Checkmate 067报道。

研究设计与样本

  • 法国MelBase前瞻性多中心队列研究,纳入2013-2022年IIIc或IV期黑色素瘤一线免疫治疗患者。
  • 主要终点为36个月OS,次要终点包括36个月PFS、最佳影像学缓解及安全性。
  • 采用逆概率治疗加权(IPTW)倾向评分校正混杂因素,并进行脑转移、LDH水平及BRAF突变状态亚组分析。

主要发现

  • 36个月OS:I+N组57.1%(95%CI 50.7-64.2) vs N组46.6%(95%CI 41.6-52.1),HR=1.4(95%CI 1.1-1.8)。
  • 36个月PFS:I+N组42.3% vs N组21.9%,HR=1.6(95%CI 1.4-1.9)。
  • ORR两组均为44%。
  • 总体不良反应发生率:N组82% vs I+N组84%。
  • ≥3级严重毒性:I+N组41% vs N组29%,差异未达统计学显著。

临床怎么用

  • 真实世界数据支持I+N双免疫联合作为转移性黑色素瘤一线治疗选择。
  • I+N方案PFS获益明确,但需关注≥3级毒性风险(本研究中41% vs 29%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Checkmate 067 randomized controlled trial, published in 2015, demonstrated improved progression-free survival (PFS) and numerically, although not statistically, superior overall survival (OS) for ipilimumab + nivolumab (I + N). OBJECTIVES: The objective of this study was to compare the efficacy and safety of N with I + N as first-line treatment for metastatic melanoma in a real-world setting. METHODS: Patients were prospectively included in the French MelBase cohort from 2013 to 2022. Eligible patients were those in first-line treatment for stage IIIc or IV melanoma, undergoing immunotherapy with N or I + N. The primary endpoint was OS at 36 months. The secondary endpoints included PFS at 36 months, best radiological response, and safety analyses. We conducted a propensity score using the inverse probability of treatment weighting (IPTW) method to overcome the various confounding factors and also a subgroup analysis (brain metastasis, lactate dehydrogenase levels and BRAF mutation status). RESULTS: Patients were treated with N (n = 406) or I + N (n = 416). OS at 36 months was higher in the I + N group at 57.1% [95% confidence interval (CI) 50.7-64.2] than in the N group [46.6% (95% CI 41.6-52.1)]; hazard ratio (HR) 1.4 (95% CI 1.1-1.8). PFS at 36 months was significantly improved in the I + N group (42.3%) compared with the N group (21.9%), with a HR of 1.6 (95% CI 1.4-1.9). The objective response rate (ORR) was similar for the two groups (44%). The overall incidence of side-effects was comparable (82% vs. 84%), and severe toxicity (grade ≥ 3) was more frequent, although not significantly so, in the I + N arm vs. the N arm (41% vs. 29%). CONCLUSIONS: Our results are consistent with those from the Checkmate 067 study, except for the ORR and the incidence of toxicities, which proved to be lower in our analysis. Over recent decades, we have seen an increase in the incidence of melanomas at all stages. New therapies, including immunotherapy, have improved the prognosis for metastatic melanoma (MM). Immunotherapy is now widely prescribed for treating metastatic forms. It is used as an adjuvant treatment (after the primary treatment) to prevent relapse. Recent research has shown the efficacy of immunotherapy, in particular, dual immunotherapy. Our study is of more than 800 patients with MM from a large French multicentre cohort. We compared nivolumab alone and ipilimumab with nivolumab (I + N) as a first-line therapy in real life for patients with MM. We saw a clear improvement in progression-free survival with dual immunotherapy (I + N). We also saw a small improvement in overall survival, compared with nivolumab alone. We saw an increase in severe toxicities for patients treated with I + N, but less than noted in the literature. This large real-life study supports the results of randomized controlled trials to use dual immunotherapy to treat MM.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Billard K, Mortier L, Dereure O, et al. The efficacy and safety of first-line metastatic melanoma treatment with ipilimumab + nivolumab vs. nivolumab in a real-world setting. Br J Dermatol. 2025. PMID: 39605282. doi:10.1093/bjd/ljae470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。